Trial Profile
Examination of the treatment prediction factor of Ombitasvir/Paritaprevir/Ritonavir in chronic hepatitis C of Genotype1b.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Apr 2020 Status changed from recruiting to completed.
- 23 Jun 2017 New trial record